Hidrosaluretil (Hydrochlorothiazide)

Hidrosaluretil is indicated for several conditions where reduction of excess fluid or control of blood pressure is required.

• Hypertension (high blood pressure) management, often as part of combination therapy.
• Edema associated with congestive heart failure, liver cirrhosis, or renal disease.
• Fluid retention secondary to chronic kidney disease.
• Prevention of calcium‑containing kidney stones in patients with hypercalciuria.
• Adjunct therapy in resistant hypertension when other agents are insufficient.

• Hydrochlorothiazide, the active component of Hidrosaluretil, acts on the distal convoluted tubule of the nephron. It blocks the Na⁺‑Cl⁻ symporter, reducing reabsorption of sodium and chloride ions. The resulting osmotic gradient promotes increased excretion of sodium, chloride, and water, leading to a reduction in extracellular fluid volume. The decrease in plasma volume contributes to lower peripheral vascular resistance and blood pressure.

Like other thiazide diuretics, Hidrosaluretil may cause a range of adverse reactions, most of which are mild and reversible.

Common

• Increased urination (polyuria).
• Mild electrolyte changes, especially low potassium.
• Dizziness or light‑headedness upon standing.

Serious

• Severe electrolyte imbalance causing cardiac arrhythmias.
• Acute gout flare due to raised uric acid.
• Significant dehydration with hypotension.

Before starting Hidrosaluretil, clinicians should evaluate patient history and monitor specific parameters to minimize risks.

• Assess renal function; avoid use in severe renal impairment.
• Monitor serum electrolytes, especially potassium and sodium, during therapy.
• Use cautiously in patients with a history of gout or hyperuricemia.
• Evaluate blood glucose levels in diabetic patients, as thiazides may raise glucose.
• Review concurrent use of other diuretics or antihypertensives to prevent excessive volume loss.
• Consider pregnancy status; safety data are limited.
• Advise patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness.

Hidrosaluretil can affect the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may reduce diuretic efficacy.
• Combination with other potassium‑depleting agents (e.g., loop diuretics, corticosteroids) that increase risk of hypokalemia.
• Co‑administration with lithium, which can raise lithium levels and toxicity.

Use with caution

• ACE inhibitors, ARBs, or beta‑blockers, as additive blood‑pressure lowering may cause hypotension.
• Antidiabetic agents, because thiazides may impair glucose control.
• Digoxin, due to potential electrolyte‑related sensitization.
• Anticoagulants, as volume depletion can affect drug concentration.